Overview

Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.

Status:
Active, not recruiting

Trial end date:
2020-06-01

Target enrollment:

Participant gender:

Summary

This study investigates the effectiveness of a simple treatment to prevent proliferative vitreoretinopathy (PVR). Intraoperative intravitreal 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) is used as a prophylactic therapy in high-risk patients with primary rhegmatogenous retinal detachment (RRD). Our major motivation is to reduce the incidence of PVR in the group that receives the trial drug.

Phase:

Phase 3

Details

Lead Sponsor:

Universitätsklinikum Köln

Collaborators:

German Research Foundation
Institute of Medical Statistics, Informatics and Epidemiology (IMSIE)
Pharmacy of the University Hospital Erlangen
The Clinical Trials Centre Cologne

Treatments:

Calcium heparin
Dalteparin
Fluorouracil
Heparin
Heparin, Low-Molecular-Weight
Tinzaparin